Form SC 13G Sarepta Therapeutics, Filed by: FMR LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
February 9, 2018 11:51 AM ESTWilliam Blair analyst Tim Lugo came out to deafened Sarepta Therapeutics (NASDAQ: SRPT) following reports of a U.K.-specific hold on further dosing of patients enrolled in Sareptas global Phase III ESSENCE trial of golodirsen.
Lugo sees the concerns as "overblown".
To wit... "We see todays roughly 6% sell-off... More
